Company
Overview
Board Members
Company History
Business
Business Overview
Business Model
Technology
Cell-free Membrane Protein Synthesis Technology
Non-canonical Amino Acid Incorporation Technology
Partnering
News
Locations
JP
Company
Overview
Board Members
Company Mistory
Bussiness
Business Overview
Business Model
Technology
Cell-free Membrane Protein Synthesis Technology
Non-canonical Amino Acid Incorporation Technology
Partnering
News
Locations
Contact Us
JP
We contribute to medical care through innovative
drug discovery using the technologies of cell-free
membrane protein preparation and non-canonical
amino acid incorporation into target proteins.
News
2024/08/01
LiberoThera Closes 720 Million JPY of Additional Funding to Accelerate the Discovery and Development of its Antibody-based Therapeutics
2024/04/03
Presentation of anti-CCR8 antibody data at the American Association for Cancer Research Annual Meeting 2024
2022/10/03
Renewed our website.
2022/07/21
LiberoThera and Biocytogen Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs
2022/06/01
Announced relocation of research laboratory.
View More
Locations
Contact Us